We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Is Prothena (PRTA) Up 4.5% Since the Last Earnings Report?
Read MoreHide Full Article
It has been about a month since the last earnings report for Prothena Corporation PLC (PRTA - Free Report) . Shares have added about 4.5% in that time frame, outperforming the market.
Will the recent positive trend continue leading up to the stock’s next earnings release, or is it due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.
Prothena Reports Wider-than-Expected Loss in Q4
Prothena reported a loss of $1.41 per share in the fourth quarter of 2016, wider than both the Zacks Consensus Estimate of a loss of $1.24 and the year-ago loss of $0.76.
Moreover, quarterly revenues came in at $0.2 million, down 44.3% primarily due to lower contributions from the collaboration agreement with Roche Holding AG. Revenues missed the Zacks Consensus Estimate of $0.3 million as well.
Quarter in Detail
Research and development (R&D) expenses were $39.8 million, up 122.7% year over year primarily due to increased expenses for product manufacturing, clinical trials and personnel costs.
General and administrative (G&A) expenses were $9.6 million, up 44.9% year over year due to higher personnel costs.
2016 Results
Revenues came in at $1.0 million, down from $1.6 million in 2015 and missed the Zacks Consensus Estimate of $1.2 million. Loss per share came in at $4.66 compared to a net loss of $2.66 per share in 2015 and wider than the Zacks Consensus Estimate of a loss of $4.50 per share.
2017 Outlook
Prothena expects net cash burn from operating and investing activities in the range of $160–$170 million. The projected range included an expected milestone payment from Roche upon initiation of the phase II study on PRX002. The company expects to end 2017 with approximately $224 million in cash, cash equivalents and restricted cash (midpoint).
Pipeline Updates
Prothena continues to progress with the candidates in its pipeline. The company is evaluating its lead candidate NEOD001 in the phase III VITAL Amyloidosis study in newly diagnosed treatment-naïve patients with AL amyloidosis and cardiac dysfunction. Patient enrollment in the VITAL study is expected to be completed in the second quarter of 2017.
Earlier, Prothena presented encouraging results from a phase I/II study on NEOD001. The results showed improvement in three organ systems (cardiac, renal and peripheral nerve) in previously treated patients with AL amyloidosis upon treatment with NEOD001.
Prothena is also evaluating the candidate in a phase IIb study, PRONTO, in previously treated patients with AL amyloidosis and persistent cardiac dysfunction. The company expects to complete enrollment in this study during the last week of February. Top-line results from the study are expected following the 12-month study period in the second quarter of 2018.
Moreover, Prothena is evaluating PRX002, in collaboration with Roche, for the treatment of Parkinson’s disease and other related synucleinopathies. The company expects to initiate a phase II study in patients with Parkinson`s disease in 2017.
The company expects to report top-line data from a phase Ib multiple ascending dose, proof-of-biology study on PRX003 in patients with psoriasis in the third quarter of 2017.
Alongside, Prothena is also working to advance PRX004 in a phase I study in patients with ATTR amyloidosis. The candidate is expected to enter clinic in 2018.
How Have Estimates Been Moving Since Then?
Following the release, investors have witnessed a downward trend in fresh estimates. There have been two downward revisions for the current quarter. In the past month, the consensus estimate has shifted downward by 83.5% due to these changes.
At this time, Prothena's stock has a poor Growth Score of 'F', however its Momentum is doing a bit better with a 'D'. Charting a somewhat similar path, the stock was allocated a grade of 'F' on the value side, putting it in the bottom quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of 'F'. If you aren't focused on one strategy, this score is the one you should be interested in.
Our style scores indicate that investors will probably be better served looking elsewhere.
Outlook
Estimates have been broadly trending downward for the stock. The magnitude of these revisions also indicates a downward shift. Notably, the stock has a Zacks Rank #3 (Hold). We are expecting an inline return from the stock in the next few months.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Why Is Prothena (PRTA) Up 4.5% Since the Last Earnings Report?
It has been about a month since the last earnings report for Prothena Corporation PLC (PRTA - Free Report) . Shares have added about 4.5% in that time frame, outperforming the market.
Will the recent positive trend continue leading up to the stock’s next earnings release, or is it due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.
Prothena Reports Wider-than-Expected Loss in Q4
Prothena reported a loss of $1.41 per share in the fourth quarter of 2016, wider than both the Zacks Consensus Estimate of a loss of $1.24 and the year-ago loss of $0.76.
Moreover, quarterly revenues came in at $0.2 million, down 44.3% primarily due to lower contributions from the collaboration agreement with Roche Holding AG. Revenues missed the Zacks Consensus Estimate of $0.3 million as well.
Quarter in Detail
Research and development (R&D) expenses were $39.8 million, up 122.7% year over year primarily due to increased expenses for product manufacturing, clinical trials and personnel costs.
General and administrative (G&A) expenses were $9.6 million, up 44.9% year over year due to higher personnel costs.
2016 Results
Revenues came in at $1.0 million, down from $1.6 million in 2015 and missed the Zacks Consensus Estimate of $1.2 million. Loss per share came in at $4.66 compared to a net loss of $2.66 per share in 2015 and wider than the Zacks Consensus Estimate of a loss of $4.50 per share.
2017 Outlook
Prothena expects net cash burn from operating and investing activities in the range of $160–$170 million. The projected range included an expected milestone payment from Roche upon initiation of the phase II study on PRX002. The company expects to end 2017 with approximately $224 million in cash, cash equivalents and restricted cash (midpoint).
Pipeline Updates
Prothena continues to progress with the candidates in its pipeline. The company is evaluating its lead candidate NEOD001 in the phase III VITAL Amyloidosis study in newly diagnosed treatment-naïve patients with AL amyloidosis and cardiac dysfunction. Patient enrollment in the VITAL study is expected to be completed in the second quarter of 2017.
Earlier, Prothena presented encouraging results from a phase I/II study on NEOD001. The results showed improvement in three organ systems (cardiac, renal and peripheral nerve) in previously treated patients with AL amyloidosis upon treatment with NEOD001.
Prothena is also evaluating the candidate in a phase IIb study, PRONTO, in previously treated patients with AL amyloidosis and persistent cardiac dysfunction. The company expects to complete enrollment in this study during the last week of February. Top-line results from the study are expected following the 12-month study period in the second quarter of 2018.
Moreover, Prothena is evaluating PRX002, in collaboration with Roche, for the treatment of Parkinson’s disease and other related synucleinopathies. The company expects to initiate a phase II study in patients with Parkinson`s disease in 2017.
The company expects to report top-line data from a phase Ib multiple ascending dose, proof-of-biology study on PRX003 in patients with psoriasis in the third quarter of 2017.
Alongside, Prothena is also working to advance PRX004 in a phase I study in patients with ATTR amyloidosis. The candidate is expected to enter clinic in 2018.
How Have Estimates Been Moving Since Then?
Following the release, investors have witnessed a downward trend in fresh estimates. There have been two downward revisions for the current quarter. In the past month, the consensus estimate has shifted downward by 83.5% due to these changes.
Prothena Corporation PLC Price and Consensus
Prothena Corporation PLC Price and Consensus | Prothena Corporation PLC Quote
VGM Scores
At this time, Prothena's stock has a poor Growth Score of 'F', however its Momentum is doing a bit better with a 'D'. Charting a somewhat similar path, the stock was allocated a grade of 'F' on the value side, putting it in the bottom quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of 'F'. If you aren't focused on one strategy, this score is the one you should be interested in.
Our style scores indicate that investors will probably be better served looking elsewhere.
Outlook
Estimates have been broadly trending downward for the stock. The magnitude of these revisions also indicates a downward shift. Notably, the stock has a Zacks Rank #3 (Hold). We are expecting an inline return from the stock in the next few months.